Back to Journals » Clinical Ophthalmology » Volume 7

Assessment of dry eye signs and symptoms and ocular tolerance of a preservative-free lacrimal substitute (Hylabak®) versus a preserved lacrimal substitute (Systane®) used for 3 months in patients after LASIK

Authors Astakhov YS, Astakhov SY, Lisochkina AB, Stolz J

Received 24 June 2013

Accepted for publication 3 August 2013

Published 9 December 2013 Volume 2013:7 Pages 2289—2297

DOI https://doi.org/10.2147/OPTH.S50446

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2



Yuri S Astakhov, Sergei Y Astakhov, Alla B Lisochkina

University Department of Ophthalmology, State Educational Establishment of Higher Professional Education, Saint Petersburg Pavlov State Medical University and of the Federal Service for Surveillance of Healthcare and Social Development of the Russian Federation, St Petersburg, Russia

Abstract: Laser-assisted in situ keratomileusis (LASIK) is commonly used to correct refractive defects. The procedure frequently results in dry eye symptoms, usually of short but sometimes longer duration. This study was designed to assess dry eye and ocular tolerability after LASIK in patients treated with a preservative-free lacrimal substitute (Hylabak®) or preserved lacrimal substitute (Systane®). In a single-center, investigator-masked, prospective, noninferiority, clinical study, patients undergoing LASIK surgery were randomized to receive Hylabak or Systane eye drops (one drop in each eye four times daily for 3 months). Fluorescein test scores were the primary efficacy variable and were similar on day 1 (mean 0.26 and 0.28 for Hylabak and Systane, respectively). At the final visit (day 84 ± 3) the fluorescein scores had improved to 0.11 and 0.04, respectively. The difference was not significant and thus noninferiority was established. A trend of more rapid improvement in the Hylabak group was evident. Both treatments were well tolerated and there were no serious adverse events, discontinuations for adverse events or other safety-related reasons, and no systemic adverse events. The results suggest that Hylabak is not less effective than Systane in reducing the symptoms of dry eye after LASIK surgery.

Keywords: dry eye, laser-assisted in situ keratomileusis, hyaluronate

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.